ArticleEJNMMI radiopharmacy and chemistry2026
Scaling the production of bromine-76 and bromine-77 labeled poly-ADP-ribose-polymerase-targeted theranostics for preclinical use.
Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBromine-76, a positron emitting radionuclide for positron emission tomography (PET) imaging, and bromine-77, an Auger electron (Ae) emitting radionuclide, make a unique halogen theranostic pair. These isotopes have previously been used to synthesize a rucaparib-derived, poly-ADP-ribose polymerase inhibitor ([
resultsIsotopically enriched cobalt selenide targets had production yields of 50.7 ± 8.7 MBq/µAh for bromine-76 and 14.5 ± 3.3 MBq/µAh for bromine-77, consistent with previous reports. Adoption of the GE PETtrace Solid Target Platform (STP) increased target backing diameter to 22 mm. Increasing dry distillation duration from 5 to 6 min to 8-9 min and furnace temperature from 1050 to 1055 °C released 94 ± 5% (n = 17) of activity, in agreement with previous smaller targets (92 ± 13%, n = 35). Rinsing glassware and loading the quaternary methyl ammonium (QMA) anion exchange cartridge in 1 mM sodium bicarbonate reduced [
conclusionThe new target production technique made targets suitable for long-term use with the GE PETtrace STP. Following modifications to the distillation process, [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.